Published in PLoS One on July 05, 2013
The funding landscape for HIV in Asia and the Pacific. J Int AIDS Soc (2015) 0.78
Innovative financing for HIV response in sub-Saharan Africa. J Glob Health (2016) 0.77
Alternative financing mechanisms for ART programs in health facilities in Uganda: a mixed-methods approach. BMC Health Serv Res (2017) 0.76
Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe. PLoS One (2015) 0.75
In the interests of time: improving HIV allocative efficiency modelling via optimal time-varying allocations. J Int AIDS Soc (2016) 0.75
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Public financing of health in developing countries: a cross-national systematic analysis. Lancet (2010) 11.22
Sexual and reproductive health in HIV-related proposals supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria. Bull World Health Organ (2009) 4.56
The end of poverty: economic possibilities for our time. Eur J Dent Educ (2008) 4.42
The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff (Millwood) (2011) 2.21
Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics (2011) 1.89
Government health expenditures and health outcomes. Health Econ (2007) 1.40
Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy (2012) 1.31
What should a country spend on health care? Health Aff (Millwood) (2007) 1.24
Study raises questions about measurement of 'additionality,'or maintaining domestic health spending amid foreign donations. Health Aff (Millwood) (2012) 1.15
An analysis of how the GAVI alliance and low- and middle-income countries can share costs of new vaccines. Health Aff (Millwood) (2011) 1.14
Bigger and better? Scaling up and innovation in health aid. Health Aff (Millwood) (2007) 1.03
HIV treatment produces economic returns through increased work and education, and warrants continued US support. Health Aff (Millwood) (2012) 1.00
Global Fund faces uncertain future as cash runs low. Lancet (2002) 0.98
Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. Health Policy Plan (2012) 0.92
An evaluation of the President's Emergency Plan for AIDS Relief effect on health systems strengthening in sub-Saharan Africa. J Acquir Immune Defic Syndr (2013) 0.90
Has HIV/AIDS displaced other health funding priorities? Evidence from a new dataset of development aid for health. Soc Sci Med (2011) 0.87
The Global Fund at three years--flying in crowded air space. Trop Med Int Health (2005) 0.85
[The Global Fund to fight HIV/AIDS, TB and Malaria 5-y: evaluation policy issues]. Bull Soc Pathol Exot (2010) 0.85
Pattern and levels of spending allocated to HIV prevention programs in low- and middle-income countries. BMC Public Health (2012) 0.84
Australia's contribution to global health fund provokes dismay. BMJ (2004) 0.78
The burden of malaria mortality among African children in the year 2000. Int J Epidemiol (2006) 6.64
Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ (2002) 4.47
HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis (2006) 2.82
Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One (2012) 2.39
Estimating the resources needed and savings anticipated from roll-out of adult male circumcision in Sub-Saharan Africa. PLoS One (2008) 2.31
Child coverage with mosquito nets and malaria treatment from population-based surveys in african countries: a baseline for monitoring progress in roll back malaria. Am J Trop Med Hyg (2004) 2.01
Pediatric mortality in Africa: plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg (2004) 1.98
Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: Simulation results. Sex Transm Dis (2006) 1.91
Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries. Pharmacoeconomics (2011) 1.89
Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. Lancet (2013) 1.85
Estimating the number of insecticide-treated nets required by African households to reach continent-wide malaria coverage targets. JAMA (2007) 1.74
Lives saved by Global Fund-supported HIV/AIDS, tuberculosis and malaria programs: estimation approach and results between 2003 and end-2007. BMC Infect Dis (2010) 1.67
Methodological and policy limitations of quantifying the saving of lives: a case study of the Global Fund's approach. PLoS Med (2013) 1.65
Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials?: A modeling study. J Acquir Immune Defic Syndr (2004) 1.65
Lives saved by tuberculosis control and prospects for achieving the 2015 global target for reducing tuberculosis mortality. Bull World Health Organ (2011) 1.64
Higher risk behaviour and rates of sexually transmitted diseases in Mwanza compared to Uganda may help explain HIV prevention trial outcomes. AIDS (2003) 1.63
Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy (2012) 1.31
Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One (2011) 1.16
Impact of over-the-counter restrictions on antibiotic consumption in Brazil and Mexico. PLoS One (2013) 1.11
Heterogeneous effects of health insurance on out-of-pocket expenditure on medicines in Mexico. Value Health (2012) 1.10
The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis. PLoS One (2013) 1.04
Outcomes and impact of HIV prevention, ART and TB programs in Swaziland--early evidence from public health triangulation. PLoS One (2013) 1.04
The anatomy of a malaria disaster: drug policy choice and mortality in African children. Lancet Infect Dis (2007) 0.96
Malaria risk: estimating clinical episodes of malaria. Nature (2005) 0.95
Regulation of antibiotic sales in Mexico: an analysis of printed media coverage and stakeholder participation. BMC Public Health (2012) 0.95
[Antibiotic use in Mexico: review of problems and policies]. Salud Publica Mex (2008) 0.93
Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. Health Policy Plan (2012) 0.92
Quantifying HIV-1 transmission due to contaminated injections. Proc Natl Acad Sci U S A (2007) 0.88
Optimizing HIV treatment programs. Curr Opin HIV AIDS (2010) 0.87
Organizational elements of health service related to a reduction in maternal mortality: the cases of Chile and Colombia. Health Policy (2008) 0.86
Strategies and ethical considerations for the recruitment of young men who have sex with men: challenges of a vaccination trial in Mexico. Clin Trials (2009) 0.84
A new entity for the negotiation of public procurement prices for patented medicines in Mexico. Bull World Health Organ (2012) 0.80
[The debate on self medication]. Salud Publica Mex (2009) 0.79
Reforming antiretroviral price negotiations and public procurement: the Mexican experience. Health Policy Plan (2012) 0.79
Scaling-up antiretroviral treatment in resource-poor countries: prioritization and choices. AIDS (2011) 0.78
Ambulatory health service users' experience of waiting time and expenditure and factors associated with the perception of low quality of care in Mexico. BMC Health Serv Res (2010) 0.78
Operational rules for the implementation of INN prescribing. Int J Med Inform (2013) 0.78
Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico. Bull World Health Organ (2012) 0.77
[Supply prescription filling and out-of-pocket expenditures on medicines in public hospitals in Mexico in 2009]. Salud Publica Mex (2011) 0.76
Improving access to treatment for HIV in sub-Saharan Africa. BMJ (2010) 0.75
Measuring universities' commitments to global health. Lancet (2013) 0.75
[Research to support pharmaceutical policies]. Salud Publica Mex (2008) 0.75
Access to medicines among internally displaced and non-displaced people in urban areas in Colombia. Cad Saude Publica (2012) 0.75